Ignacio Escobar
YOU?
Author Swipe
View article: Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design Open
The trial started recruitment on March 2023.
View article: Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol
Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol Open
Background The therapeutic landscape in generalized myasthenia gravis (gMG) has been continuously evolving in recent years, with over five products approved, each with different efficacy, safety, and administration profiles. With the avail…
View article: Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry
Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry Open
Background: Patient registries better reflect real-world management and outcomes of pancreatic cancer (PC) compared with clinical trials. Patients and methods: The main objective was to characterize patterns of care and outcomes in patient…
View article: Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding Open
Patients with cancer present a higher risk of rethrombosis and bleeding secondary to anticoagulant treatment than individuals without cancer. Given the lack of specific clinical trials, the decision regarding the optimal duration of treatm…
View article: Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study Open
Background Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary…
View article: Potential Impact of Omega 6/3 Ratio and CD68+ Macrophage Infiltration on Survival in NSCLC Patients Undergoing Pulmonary Resection
Potential Impact of Omega 6/3 Ratio and CD68+ Macrophage Infiltration on Survival in NSCLC Patients Undergoing Pulmonary Resection Open
Background: Lung cancer remains the leading cause of cancer-related mortality worldwide with non-small cell lung cancer (NSCLC) accounting for the majority of cases. The stage of detection significantly influences survival rates with early…
View article: Update on the management of elderly patients with colorectal cancer
Update on the management of elderly patients with colorectal cancer Open
Colorectal cancer (CRC) is one of the most common tumours worldwide, and 70% of CRC patients are over 65 years of age. However, the scientific evidence available for these patients is poor, as they are underrepresented in clinical trials. …
View article: A Comparison of Total Thoracoscopic and Robotic Surgery for Lung Cancer Lymphadenectomy
A Comparison of Total Thoracoscopic and Robotic Surgery for Lung Cancer Lymphadenectomy Open
Background: Robotic-assisted thoracic surgery (RATS) is used increasingly frequently in major lung resection for early stage non-small-cell lung cancer (NSCLC) but has not yet been fully evaluated. The aim of this study was to compare the …
View article: Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group
Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group Open
Purpose The CoVID-TE model was developed with the aim of predicting venous thrombotic events (VTE) in cancer patients with Sars-Cov-2 infection. Moreover, it was capable of predicting hemorrhage and mortality 30 days following infection di…
View article: Data from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Data from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
Purpose: The microRNA-34b/c (miR-34b/c) is considered a tumor suppressor in different tumor types and a transcriptional target of TP53. The main objectives of this study were to investigate the clinical implications of miR-34b/c methylatio…
View article: Supplementary Figure S3 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S3 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 68K, Frequency of miR-34b/c promoter methylation and correlation of tumors miR-34b/c expression with methylation status
View article: Data from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Data from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
Purpose: The microRNA-34b/c (miR-34b/c) is considered a tumor suppressor in different tumor types and a transcriptional target of TP53. The main objectives of this study were to investigate the clinical implications of miR-34b/c methylatio…
View article: Supplementary Figure S5 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S5 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 74K, Kaplan-Meier plot of DFS according to miR-34b/c methylation level in 97 stage I lung AC patients
View article: Supplementary Figure S5 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S5 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 74K, Kaplan-Meier plot of DFS according to miR-34b/c methylation level in 97 stage I lung AC patients
View article: Supplementary Figure S7 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S7 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 103K, Cisplatin chemosensitivity in SK-LU-1 miR-34b/c transfected cells
View article: Supplementary Figure S4 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S4 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 88K, Kaplan-Meier plots of DFS and OS according to miR-34b/c methylation in 140 early stage lung AC patients
View article: Supplementary Tables S1-S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Tables S1-S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file115K, Suppl.Table S1. Patient characteristics. Suppl.Table S2. Lung AC lines with TP53 mutation. Suppl.Table S3. Primers used for qRT-PCR. Suppl.Table S4. Correlation between tumors miR-34b/c expression and clinical and molecular v…
View article: Supplementary Figure S2 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S2 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 167K, Restoration of miR-34b/c expression by treating lung AC cell lines with 5-Aza-2'-Deoxycytidine
View article: Supplementary Figure S8 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S8 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 263K, Representative examples of invasion assay in SK-LU-1 cells
View article: Supplementary Figure S7 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S7 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 103K, Cisplatin chemosensitivity in SK-LU-1 miR-34b/c transfected cells
View article: Supplementary Figure S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 160K, Characterization of miR-34b/c transfectants
View article: Supplementary Figure S8 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S8 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 263K, Representative examples of invasion assay in SK-LU-1 cells
View article: Supplementary Figure S1 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Figure S1 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file 193K, Analytical sensitivity of Melting Curve Analysis for assessing miR-34b/c methylation
View article: Supplementary Tables S1-S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Supplementary Tables S1-S6 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma Open
PDF file115K, Suppl.Table S1. Patient characteristics. Suppl.Table S2. Lung AC lines with TP53 mutation. Suppl.Table S3. Primers used for qRT-PCR. Suppl.Table S4. Correlation between tumors miR-34b/c expression and clinical and molecular v…